Pacira BioSciences [PCRX] vs Zoetis [ZTS] Detailed Stock Comparison

Pacira BioSciences Inc.

NASDAQ
Loading...

Zoetis Inc.

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Pacira BioSciences Inc. wins in 8 metrics, Zoetis Inc. wins in 11 metrics, with 0 ties. Zoetis Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Pacira BioSciences Inc. Zoetis Inc. Better
P/E Ratio (TTM) 154.00 19.58 Zoetis Inc.
Price-to-Book Ratio 1.46 15.04 Pacira BioSciences Inc.
Debt-to-Equity Ratio 60.34 279.59 Pacira BioSciences Inc.
PEG Ratio -1.74 2.81 Zoetis Inc.
EV/EBITDA 9.47 13.96 Pacira BioSciences Inc.
Profit Margin (TTM) 0.97% 28.24% Zoetis Inc.
Operating Margin (TTM) -1.17% 34.69% Zoetis Inc.
EBITDA Margin (TTM) N/A 34.69% N/A
Return on Equity 0.96% 65.99% Zoetis Inc.
Return on Assets (TTM) 1.48% 15.26% Zoetis Inc.
Free Cash Flow (TTM) $136.66M $2.28B Zoetis Inc.
Dividend Yield N/A 1.21% N/A
1-Year Return -10.14% -53.93% Pacira BioSciences Inc.
Price-to-Sales Ratio (TTM) 1.46 5.26 Pacira BioSciences Inc.
Enterprise Value $1.18B $56.75B Zoetis Inc.
EV/Revenue Ratio 1.62 6.00 Pacira BioSciences Inc.
Gross Profit Margin (TTM) 79.53% 70.17% Pacira BioSciences Inc.
Revenue per Share (TTM) $16 $21 Zoetis Inc.
Earnings per Share (Diluted) $0.16 $6.02 Zoetis Inc.
Beta (Stock Volatility) 0.20 0.97 Pacira BioSciences Inc.
Short % of Float 29.98% 4.06% Zoetis Inc.

Pacira BioSciences Inc. vs Zoetis Inc. Stock Performance Analysis

Loading Price Chart...

PCRX
ZTS

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Pacira BioSciences Inc.0.31%-8.70%-9.92%4.51%-7.60%-9.08%
Zoetis Inc.1.51%-4.46%-31.75%-39.76%-38.95%-38.30%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Pacira BioSciences Inc.-10.14%-40.60%-61.90%-50.69%67.77%230.30%
Zoetis Inc.-53.93%-54.80%-55.66%62.09%150.53%150.53%

Performance & Financial Health Analysis: Pacira BioSciences Inc. vs Zoetis Inc.

MetricPCRXZTS
Market Information
Market Cap i$1.09B$49.75B
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i455,1442,727,710
90 Day Avg. Volume i642,2013,835,940
Last Close$22.32$167.10
52 Week Range$18.80 - $27.64$139.70 - $200.33
% from 52W High-19.25%-16.59%
All-Time High$121.95 (Feb 23, 2015)$249.27 (Dec 27, 2021)
% from All-Time High-81.70%-32.96%
Growth Metrics
Quarterly Revenue Growth0.05%0.03%
Quarterly Earnings Growth-0.90%0.04%
Financial Health
Profit Margin (TTM) i0.01%0.28%
Operating Margin (TTM) i-0.01%0.35%
Return on Equity (TTM) i0.01%0.66%
Debt to Equity (MRQ) i60.34279.59
Cash & Liquidity
Book Value per Share (MRQ)$16.86$7.84
Cash per Share (MRQ)$5.89$5.48
Operating Cash Flow (TTM) i$151.99M$2.90B
Levered Free Cash Flow (TTM) i$108.56M$1.79B
Dividends
Last 12-Month Dividend Yield iN/A1.21%
Last 12-Month Dividend iN/A$2.03

Valuation & Enterprise Metrics Analysis: Pacira BioSciences Inc. vs Zoetis Inc.

MetricPCRX (Apr 24, 2026)ZTS (Apr 13, 2026)
Price Ratios
P/E Ratio (TTM) i154.0019.58
Forward P/E i7.0215.61
PEG Ratio i-1.742.81
Price to Sales (TTM) i1.465.26
Price to Book (MRQ) i1.4615.04
Market Capitalization
Market Capitalization i$1.09B$49.75B
Enterprise Value i$1.18B$56.75B
Enterprise Value Metrics
Enterprise to Revenue i1.626.00
Enterprise to EBITDA i9.4713.96
Risk & Other Metrics
Beta i0.200.97
Book Value per Share (MRQ) i$16.86$7.84

Financial Statements Comparison: Pacira BioSciences Inc. vs Zoetis Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricPCRX (2025)ZTS (2025)
Revenue/Sales i726.41M9.47B
Cost of Goods Sold i149.75M2.67B
COGS % of Revenue i20.6%28.2%
Gross Profit i576.66M6.80B
Gross Margin i79.4%71.8%
Research & Development i117.31M698.00M
Operating Income (EBIT) i33.30M3.60B
Operating Margin i4.6%38.0%
EBITDA i137.60M4.17B
EBITDA Margin i18.9%44.1%
Pre-Tax Income i16.87M3.36B
Pre-Tax Income % of Revenue i2.3%35.5%
Income Tax i9.84M687.00M
Income Tax % of Revenue i1.4%7.3%
Net Income (Profit) i7.03M2.67B
Profit Margin i1.0%28.2%

Balance Sheet & Liquidity Metrics

MetricPCRX (2025)ZTS (2025)
Cash & Equivalents i158.55M2.31B
Total Current Assets i547.97M6.77B
Total Current Assets % of Revenue i75.4%71.5%
Total Current Liabilities i120.59M2.24B
Total Current Liabilities % of Revenue i16.6%23.6%
Long-Term Debt i408.37M9.24B
Long-Term Debt % of Revenue i56.2%97.6%
Total Shareholders Equity i693.11M3.33B
Retained Earnings i-199.32M13.74B
Retained Earnings % of Revenue i-27.4%145.2%
Property, Plant & Equipment i41.78M288.00M

Cash Flow Statement Comparison

MetricPCRX (2025)ZTS (2025)
Operating Cash Flow i108.50M2.78B
Operating Cash Flow % of Revenue i14.9%29.3%
Capital Expenditures i-15.33MN/A
Free Cash Flow i136.66M2.28B
FCF Margin i18.8%24.1%
Debt Repayment i-317.80M-1.35B
Common Stock Repurchase i-148.33M-3.24B

Short Interest & Institutional Ownership Analysis

MetricPCRXZTS
Shares Short i8.06M15.12M
Short Ratio i9.813.60
Short % of Float i29.98%4.06%
Shares Outstanding i41.12M424.93M
Float Shares i37.64M421.29M
% Held by Insiders i3.32%0.15%
% Held by Institutions i118.71%101.50%
% Held by Public i-22.03%-1.65%

Dividend Analysis & Yield Comparison: Pacira BioSciences Inc. vs Zoetis Inc.

MetricPCRXZTS
Last 12-Month Dividend iN/A$2.03
Last 12-Month Dividend Yield iN/A1.21%
3-Year Avg Annual Dividend iN/A$1.80
3-Year Avg Dividend Yield iN/A0.29%
3-Year Total Dividends iN/A$5.39
Ex-Dividend DateN/AJan 20, 2026